16:48:39 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-12 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-20 Ordinarie utdelning SCIB 0.00 SEK
2024-05-17 Årsstämma 2024
2024-05-09 Kvartalsrapport 2024-Q1
2024-02-22 Bokslutskommuniké 2023
2023-11-10 Kvartalsrapport 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-19 Ordinarie utdelning SCIB 0.00 SEK
2023-05-17 Årsstämma 2023
2023-05-10 Kvartalsrapport 2023-Q1
2023-02-13 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning SCIB 0.00 SEK
2022-05-18 Årsstämma 2022
2022-05-12 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-09-07 Extra Bolagsstämma 2021
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-19 Ordinarie utdelning SCIB 0.00 SEK
2021-05-18 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-19 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 Årsstämma 2020
2020-05-15 Ordinarie utdelning SCIB 0.00 SEK
2020-05-05 Kvartalsrapport 2020-Q1
2020-04-29 Extra Bolagsstämma 2020
2020-02-21 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-17 Ordinarie utdelning SCIB 0.00 SEK
2019-05-16 Årsstämma 2019
2019-05-10 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-20 Kvartalsrapport 2018-Q2
2018-05-17 Ordinarie utdelning SCIB 0.00 SEK
2018-05-16 Årsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-02-20 Bokslutskommuniké 2017
2017-11-15 Extra Bolagsstämma 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-17 Ordinarie utdelning SCIB 0.00 SEK
2017-05-16 Årsstämma 2017
2017-05-10 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-14 Kvartalsrapport 2016-Q3
2016-08-19 Kvartalsrapport 2016-Q2
2016-05-17 Ordinarie utdelning SCIB 0.00 SEK
2016-05-16 Årsstämma 2016
2016-05-13 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-11-12 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
SciBase Holding är verksamt inom medicinteknik. Koncernen är specialiserad inom hantering av cancerdiagnostik, främst inriktat mot behandling och upptäckandet av diverse melanom. Bolaget har utvecklat en elektrisk handhållen sond som analyserar mätsignalen för att upptäcka specifika förändringar i kroppens hudvävnad. Huvudkontoret ligger i Stockholm.
2019-11-13 08:00:00

January 1 - September 30, 2019

The third quarter in figures
  • Net sales amounted to TSEK 1,940 (1,359).
  • The loss after tax amounted to TSEK 9,868 (12,754).
  • The loss per share amounted to SEK 0.59 (0.77).
  • The cash flow from current operations was negative in the amount of TSEK 10,264 (7,692).
  • The gross margin reached 53.4% (52.6%).
  • Electrode sales volume increased by 54% and reached 4,752 (3,088) units. Repeat sales of electrodes to existing customers increased by 63%.
The first 9-months in figures
  • Net sales amounted to TSEK 6,476 (4,869).
  • The loss after tax amounted to TSEK 29,387 (32,709).
  • The loss per share amounted to SEK 1,77 (1.97).
  • The cash flow from current operations was negative in the amount of TSEK 29,114 (27,492).
  • The gross margin increased to 53.1% (51.9%).
  • Electrode sales volume increased by 43% and reached 16,544 (11,606) units. Repeat sales of electrodes to existing customers increased by 53%.
Important events during the quarter
  • Sales in the company's key market Germany continue to grow and increased by 36% in the quarter following a further improvement in electrode sales. Total sales increased by 43%
  • In the period the first sale and shipment of SciBase products for the evaluation of skin barrier function was made. The first shipment is to a prestigious hospital in Japan for research into skin barrier function in infants.
  • New Nevisense software was released in the EU that included wireless integration with the Heine digital dermoscopy system, skin barrier analysis tools and further ease-of-use improvements.
Important events after the end of the     period
  • SciBase receives the first multi system order from a large US dermatology practice group. Advanced Dermatology, P.C. is a group of over 40 dermatology practices in the New York tri-state area.
  • SciBase receives order from the dermatology clinic at the Mount Sinai hospital in New York.
  • A nominating committee has been appointed.

          Oct 1  
2018 -
  July Jan 1 Sep 30 Jan 1 - Dec 31
1 - - Sep 2019
Sep 30
30
THE GROUP 2019 2018 2019 2018 Rolling 2018
-12
Net sales, SEK ths 1 940 1 359 6 476 4 869 8 506 6 899
Gross margin, % 53,4% 52,6% 53,1% 51,9% 52,8% 52,0%
Equity/Asset ratio, % 73,4% 89,2% 73,4% 89,2% 83,2% 88,1%
Net indebtness, multiple 0,36 0,12 0,36 0,12 0,20 0,13
Cash equivalents, SEK ths 35 77 35 77 35 917 67 514
917 551 917 551
Cashflow from operating -10 -7 -29 -27 -39 104 -37 482
activities, SEK ths 264 692 114 492
Earnings per share -0,59 -0,77 -1,77 -1,97 -2,46 -2,66
(before and after
dilution), SEK
Shareholder's equity per 2,53 4,97 2,53 4,97 3,75 4,30
share, SEK
Average number of shares, 16 16 16 16 16 618 16 618
000' 618 618 618 618
Number of shares at 16 16 16 16 16 618 16 618
closing of period, 000' 618 618 618 618
Share price at end of 5,25 4,52 5,25 4,52 5,25 3,10
period, SEK
Number of sold 4 752 3 088 16 11 20 416 15 478
electrodes, pieces 544 606
Average number of 18 19 18 20 18 19
employees

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on November 13, 2019.

Contact person: Michael Colérus, CFO. +46 70 341 34 72

For more information, please contact: 
Simon Grant, CEO SciBase 
Phone: +46 72 887 43 99 
Email: simon.grant@scibase.com

Certified Advisor: 
Avanza AB 
Phone: +46 8 409 421 20 
Email: corp@avanza.se

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company and a global leader in breakthrough point-of-care technology for the evaluation of skin disorders such as skin cancer and atopic dermatitis.  Their flagship product Nevisense assists physicians in the detection of melanoma at its earliest, most curable stage.  Melanoma is the deadliest form of skin cancer and has an almost 100% cure rate if caught early. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation in research. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and is FDA Approved in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.